All Clinical Trials

A listing of 23142 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Featured Trial

Studying an Investigational Medication's Impact on Cardiovascular Events

Recruiting

The main objectives of this Phase 3 study are to evaluate the safety and effectiveness of an investigational medication's ability to reduce major adverse cardiovascular events (such as heart attacks and strokes) in adults at risk. Participants will be randomly assigned to receive either the investigational medication or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

All Conditions

Hyperlipidemia

Cardiovascular Disease

Ischemic heart disease (IHD)

Stroke

Learn More

Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder

NCT06274567

Recruiting

The objective of this study protocol is to test whether intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) can strengthen functional connectivity with a key region in emotion regulation (ER) neurocircuitry (anterior insula, AI) and improve performance on ER-related tasks in patients with bipolar disorder. Individual IPL sites for stimulation will be identified through baseline, pre-TMS functional magnetic resonance imaging (fMRI) scans. Pa... Read More

Gender:

ALL

Ages:

Between 24 years and 65 years

Trial Updated:

04/17/2025

Locations: Martinos Center for Biomedical Imaging, Charlestown, Massachusetts +1 locations

Conditions: Bipolar Disorder

Learn More ›

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534

Recruiting

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Read Less

Gender:

ALL

Ages:

Between 2 years and 17 years

Trial Updated:

04/17/2025

Locations: UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California +71 locations

UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California

Children's Hospital Colorado - Aurora /ID# 262207, Aurora, Colorado

Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford, Connecticut

OSF St. Francis Medical Center /ID# 262192, Peoria, Illinois

Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis, Indiana

MNGI Digestive Health, P. A. /ID# 262204, Minneapolis, Minnesota

Icahn School of Medicine at Mount Sinai /ID# 262216, New York, New York

UH Cleveland Medical Center /ID# 262188, Cleveland, Ohio

Children's Hospital of Philadelphia - Main /ID# 262197, Philadelphia, Pennsylvania

Children's Hospital at Westmead /ID# 262350, Westmead, New South Wales

Queensland Children's Hospital /ID# 262351, South Brisbane, Queensland

Monash Health - Monash Medical Centre /ID# 262878, Clayton, Victoria

Perth Children'S Hospital /ID# 272905, Perth, Western Australia

Uza /Id# 261745, Edegem, Antwerpen

Cliniques Universitaires UCL Saint-Luc /ID# 261741, Bruxelles, Bruxelles-Capitale

Universitair Ziekenhuis Leuven /ID# 261740, Leuven, Vlaams-Brabant

Hospital Universite Enfants Reine Fabiola /ID# 261744, Bruxelles, Not set

CHR de la Citadelle /ID# 261749, Liege, Not set

UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 261750, Namur, Not set

Galileo Medical Research Ltda /ID# 262602, Juiz de Fora, Minas Gerais

Hospital Pequeno Príncipe /ID# 262600, Curitiba, Parana

Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 262601, Porto Alegre, Rio Grande Do Sul

Hospital Sírio Libanês /ID# 262670, São Paulo, Sao Paulo

Rocco & Nazato Servicos Medicos /ID# 262485, São Paulo, Sao Paulo

UMHAT Sveti Georgi /ID# 262590, Plovdiv, Not set

Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 262589, Sofiya, Not set

Beijing Children's Hospital /ID# 262258, Beijing, Beijing

Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 262596, Guangzhou, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 272807, Guangzhou, Guangdong

Hunan Children's Hospital /ID# 262512, Changsha, Hunan

Shengjing Hospital of China Medical University /ID# 262301, Shenyang, Liaoning

Children's Hospital of Shanghai /ID# 262356, Shanghai, Shanghai

Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 262502, Shanghai, Shanghai

Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 263422, Bron, Rhone

CHU de CAEN - Hopital de la Cote de Nacre /ID# 262311, Caen, Not set

Hopitaux de Paris (AP-HP) - Hopital Robert Debre - CHU /ID# 262308, Paris, Not set

Agia Sofia Hospital /ID# 261792, Athens, Attiki

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 261790, Athens, Attiki

University General Hospital of Heraklion PA.G.N.I /ID# 261791, Heraklion, Kriti

Fondazione di Religione e di Culto Casa Sollievo della Sofferenza /ID# 262384, San Giovanni Rotondo, Foggia

Azienda Ospedaliera Universitaria Gaetano Martino /ID# 262380, Messina, Not set

Tsujinaka Hospital Kashiwanoha /ID# 262454, Kashiwa-shi, Chiba

Kurume University Hospital /ID# 262455, Kurume-shi, Fukuoka

Miyagi Children's Hospital /ID# 262459, Sendai-shi, Miyagi

Osaka Women's and Children's Hospital /ID# 262549, Izumi-Shi, Osaka

Saga University Hospital /ID# 262753, Saga-shi, Saga

Saitama Children's Medical Center /ID# 262461, Saitama-shi, Saitama

Institute of Science Tokyo Hospital /ID# 262510, Bunkyo-ku, Tokyo

Tokyo Metropolitan Children's Medical Center /ID# 262550, Fuchu-shi, Tokyo

National Center for Child Health and Development /ID# 262456, Setagaya-ku, Tokyo

Toyama Prefectural Central Hospital /ID# 262739, Toyama-shi, Toyama

Seoul National University Hospital /ID# 262324, Seoul, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 262721, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 262323, Seoul, Seoul Teugbyeolsi

Christchurch Hospital /ID# 262577, Christchurch, Canterbury

Starship Child Health /ID# 262576, Auckland, Not set

Gastromed Sp. z o.o /ID# 262367, Torun, Kujawsko-pomorskie

Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 262366, Warszawa, Mazowieckie

Clinical Research Investigator Group, LLC /ID# 262357, Bayamon, Not set

Puerto Rico Health Institute /ID# 262358, Dorado, Not set

Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 262226, Ferrol, A Coruna

Hospital Sant Joan de Deu /ID# 262599, Esplugues de Llobregat, Barcelona

Hospital Regional Universitario de Malaga /ID# 262228, Malaga, Not set

Hospital Universitario Virgen del Rocio /ID# 262712, Sevilla, Not set

Hospital Clinico Universitario Lozano Blesa /ID# 262227, Zaragoza, Not set

National Taiwan University Hospital /ID# 261695, Taipei City, Taipei

Linkou Chang Gung Memorial Hospital /ID# 261696, Taoyuan City, Not set

Addenbrooke's Hospital /ID# 262707, Cambridge, Cambridgeshire

Sheffield Children's Hospital NHS Foundation Trust /ID# 261832, Sheffield, England

Barts Health NHS Trust /ID# 262811, London, Greater London

Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 262778, Norwich, Norfolk

Royal Hospital for Children and Young People /ID# 262388, Edinburgh, Not set

Conditions: Crohn's Disease

Learn More ›

Asthma Link Effectiveness Trial

NCT06388460

Recruiting

The goal of this cluster Randomized Control Trial is to determine the effectiveness of Asthma Link, a school supervised asthma therapy program, compared with an educational asthma workbook, in improving asthma symptoms for children with poorly controlled asthma aged 5-14.

Gender:

ALL

Ages:

Between 5 years and 14 years

Trial Updated:

04/17/2025

Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts

Conditions: Childhood Asthma

Learn More ›

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396

Recruiting

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California +29 locations

USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California

USC Norris Oncology Hematology Newport Beach ( Site 0029), Newport Beach, California

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia

CHRISTUS Highland ( Site 0005), Shreveport, Louisiana

Renown Regional Medical Center ( Site 0018), Reno, Nevada

Mays Cancer Center ( Site 0022), San Antonio, Texas

Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), Caba, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Buenos Aires

Instituto Alexander Fleming-Alexander Fleming ( Site 0505), Ciudad Autónoma de Buenos Aires, Caba

Sanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Cordoba

Instituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe

Centro de Investigación del Maule ( Site 4106), Talca, Maule

Bradfordhill ( Site 4100), Santiago., Region M. De Santiago

FALP ( Site 4102), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. De Santiago

IMAT S.A.S ( Site 1205), Monteria, Cordoba

Oncologos Del Occidente ( Site 1200), Pereira, Risaralda

Fundacion Valle del Lili ( Site 1204), Cali, Valle Del Cauca

Seoul National University Hospital ( Site 3100), Seoul, Not set

Samsung Medical Center ( Site 3101), Seoul, Not set

National Cheng Kung University Hospital ( Site 3300), Tainan, Not set

National Taiwan University Hospital ( Site 3301), Taipei, Not set

National Taiwan University Cancer Center ( Site 3302), Taipei, Not set

Faculty of Medicine - Khon Kaen University ( Site 3502), Muang, Khon Kaen

Faculty of Medicine Siriraj Hospital ( Site 3500), Bangkoknoi, Krung Thep Maha Nakhon

Songklanagarind Hospital ( Site 3501), Hat Yai, Songkhla

The Royal Cornwall Hospital ( Site 1904), Truro, England

St Bartholomews Hospital ( Site 1900), London, London, City Of

The Christie Hospital NHS Foundation Trust ( Site 1902), Withington, Manchester

Conditions: Metastatic Breast Cancer

Learn More ›

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916

Recruiting

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: Ps0039 50140, Birmingham, Alabama +15 locations

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis

Learn More ›

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515

Recruiting

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: City of Hope, Duarte, California +47 locations

City of Hope, Duarte, California

University of California, Los Angeles (UCLA), Los Angeles, California

Sarah Cannon Research Institute at HealthOne, Denver, Colorado

Sibley Memorial Hospital, Washington, District of Columbia

Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida

Emory University School of Medicine, Atlanta, Georgia

Community Health Network, Indianapolis, Indiana

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

New York University (NYU) Langone Medical Center, New York, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

USO - US Oncology Research Network, Nashville, Tennessee

Vanderbilt University School of Medicine, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin

The Ottawa Hospital, Ottawa, Ontario

Princess Margaret Hospital, Toronto, Ontario

Centre Leon Berard, Lyon, Not set

Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone, Marseille, Not set

Oncopole Claudius Regaud, Toulouse, Not set

Institut Gustave Roussy, Villejuif cedex, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Munchen, Not set

START Dublin Early Phase Clinical Trials Unit, Dublin, Not set

Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Not set

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Not set

Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set

Kanagawa cancer center, Kanagawa, Not set

National Cancer Center Hospital East, Kashiwa, Chiba, Not set

Aichi Cancer Center Hospital, Nagoya, Not set

Kansai Medical University Hospital, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

NCT06602453

Recruiting

The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.

Gender:

ALL

Ages:

40 years and above

Trial Updated:

04/17/2025

Locations: Yale School of Medicine Yale New Haven Hospital, New Haven, Connecticut +10 locations

Conditions: Acute Kidney Injury

Learn More ›

A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422

Recruiting

The goal of this study is to learn if people who receive V940 and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving V940 and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: Providence St. Jude Medical Center ( Site 0106), Fullerton, California +65 locations

Providence St. Jude Medical Center ( Site 0106), Fullerton, California

UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs, Colorado

Beacon Cancer Care ( Site 0127), Post Falls, Idaho

The University of Chicago Medical Center ( Site 0118), Chicago, Illinois

Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri

Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse, New York

Icahn School of Medicine at Mount Sinai ( Site 0116), New York, New York

Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee

MD Anderson Cancer Center ( Site 0150), Houston, Texas

The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center (, Tyler, Texas

CEMIC ( Site 2454), Caba., Buenos Aires

Fundacion Intecnus ( Site 2456), San Carlos de Bariloche, Rio Negro

Centro Médico IPAM ( Site 2452), Rosario, Santa Fe

Instituto Medico Especializado Alexander Fleming ( Site 2457), Buenos Aires, Not set

Instituto Oncologico de Cordoba -IONC ( Site 2455), Cordoba, Not set

Calvary Mater Newcastle ( Site 2106), Waratah, New South Wales

Tasman Oncology Research ( Site 2104), Southport, Queensland

Grampians Health ( Site 2101), Ballarat, Victoria

One Clinical Research ( Site 2103), Nedlands, Western Australia

Liga Norte Riograndense Contra o Cancer ( Site 2513), Natal, Rio Grande Do Norte

Hospital Tacchini ( Site 2506), Bento Goncalves, Rio Grande Do Sul

Hospital de Clínicas de Passo Fundo ( Site 2504), Passo Fundo, Rio Grande Do Sul

Hospital Moinhos de Vento ( Site 2510), Porto Alegre, Rio Grande Do Sul

Instituto de Oncologia Saint Gallen ( Site 2507), Santa Cruz do Sul, Rio Grande Do Sul

Hospital de Amor - Barretos ( Site 2511), Barretos, Sao Paulo

Queen Elizabeth II Health Sciences Centre ( Site 1101), Halifax, Nova Scotia

Lakeridge Health ( Site 1107), Oshawa, Ontario

McGill University Health Centre ( Site 1103), Montréal, Quebec

FALP ( Site 2551), Santiago., Region M. De Santiago

Orlandi Oncologia ( Site 2555), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2556), Santiago, Region M. De Santiago

Bradfordhill ( Site 2552), Santiago, Region M. De Santiago

ONCOCENTRO APYS ( Site 2554), Viña del Mar, Valparaiso

IMAT S.A.S ( Site 2602), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Sit, Bogota, Distrito Capital De Bogota

Hospital Universitario San Ignacio ( Site 2610), Bogota, Distrito Capital De Bogota

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 2604), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 2608), Pereira, Risaralda

Fundacion Valle del Lili- CIC ( Site 2601), Cali, Valle Del Cauca

Rambam Health Care Campus ( Site 1603), Haifa, Not set

Shaare Zedek Medical Center ( Site 1601), Jerusalem, Not set

Hadassah Medical Center ( Site 1605), Jerusalem, Not set

Sheba Medical Center ( Site 1602), Ramat Gan, Not set

National Hospital Organization Kyushu Cancer Center ( Site 1167), Fukuoka, Not set

Fukushima Medical University Hospital ( Site 1151), Fukushima, Not set

Hiroshima University Hospital ( Site 1165), Hiroshima, Not set

National Cancer Center ( Site 2305), Goyang-si, Kyonggi-do

The Catholic University of Korea St. Vincent s Hospital ( Site 2301), Suwonsi, Kyonggi-do

Ajou University Hospital ( Site 2306), Suwon, Kyonggi-do

Seoul National University Hospital ( Site 2303), Seoul, Not set

Severance Hospital Yonsei University Health System ( Site 2302), Seoul, Not set

Samsung Medical Center ( Site 2304), Seoul, Not set

Seoul St. Mary's Hospital ( Site 2307), Seoul, Not set

National Cancer Centre Singapore ( Site 2251), Singapore, Central Singapore

Chung Shan Medical University Hospital ( Site 2351), Taichung, Not set

China Medical University Hospital ( Site 2358), Taichung, Not set

National Cheng Kung University Hospital ( Site 2354), Tainan, Not set

Mackay Memorial Hospital ( Site 2355), Taipei, Not set

Taipei Medical University Hospital ( Site 2352), Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359), Taipei, Not set

Taipei Veterans General Hospital ( Site 2357), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 2001), Sıhhiye, Ankara

Bristol Haematology and Oncology Centre ( Site 2072), Bristol, Bristol, City Of

St Bartholomews Hospital ( Site 2052), London, London, City Of

Nottingham City Hospital ( Site 2058), Nottingham, Nottinghamshire

St James University Hospital ( Site 2055), Leeds, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT06649045

Recruiting

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at ti... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: Ark Clinical Research, Long Beach, California +77 locations

Ark Clinical Research, Long Beach, California

Peninsula Research Associates, Rolling Hills Estates, California

Artemis Institute for Clinical Research, San Diego, California

Care Access - Aurora, Aurora, Colorado

EBGS Clinical Research Center, Snellville, Georgia

Elite Clinical Trials, Blackfoot, Idaho

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative, Springfield, Illinois

Care Access - Shreveport, Shreveport, Louisiana

The Sleep Spot - Maimonides, Albuquerque, New Mexico

Accellacare - Wilmington, Wilmington, North Carolina

CTI Clinical Research Center, Cincinnati, Ohio

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh, Pennsylvania

Preferred Primary Care Physicians, Uniontown, Pennsylvania

FutureSearch Trials of Neurology, Austin, Texas

Prime Revival Research Institute, LLC, Flower Mound, Texas

Northwest Clinical Research Center, Bellevue, Washington

Centro Médico Viamonte, Buenos Aires, Ciudad Autónoma De Buenos Aires

Consultorio de Investigación Clínica EMO SRL, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires

Instituto Médico Río Cuarto, Río Cuarto, Córdoba

Centro Privado de Medicina Respiratoria, Paraná, Entre Ríos

Centro de Salud e Investigaciones Médicas, Santa Rosa, La Pampa

INECO Neurociencias Oroño, Rosario, Santa Fe

Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aires, Not set

Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul

BR Trials - Ensaios Clinicos e Consultoria, Sao Paulo, São Paulo

CPQuali Pesquisa Clínica, São Paulo, Not set

CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Not set

Hospital das Clinicas FMUSP, São Paulo, Not set

Peking University People's Hospital, Beijing, Beijing

ShenZhen People's Hospital, Shenzhen, Guangdong

The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan

Wuxi People's Hospital, Wuxi, Jiangsu

Jiangxi Provincial People's Hospital, Nanchang, Jiangxi

The First Hospital of Jilin University, Changchun, Jilin

Pudong New Area People's Hospital Shanghai, Shanghai, Shanghai

Sichuan Provincial People's Hospital, Chengdu, Sichuan

Huzhou Central Hospital, Huzhou, Zhejiang

Ningbo First Hospital, Ningbo, Zhejiang

Nemocnice Rudolfa a Stefanie Benešov, Benesov, Benešov

Milan Kvapil s.r.o., Diabetologicka ambulance, Praha, Praha 4

Praglandia s.r.o, Praha 5, Not set

Siteworks - Karlsruhe, Karlsruhe, Baden-Württemberg

CIMS Studienzentrum Bamberg, Bamberg, Bayern

Siteworks GmbH - Hannover, Hannover, Niedersachsen

InnoDiab Forschung Gmbh, Essen, Nordrhein-Westfalen

Unterfrintroper Hausarztzentrum Klinische Forschung, Essen, Nordrhein-Westfalen

Institut für Diabetesforschung GmbH Münster, Münster, Nordrhein-Westfalen

RED-Institut GmbH, Oldenburg, Schleswig-Holstein

Advanced Sleep Research, Berlin, Not set

Endolife Speciality Hospitals, Guntur, Andhra Pradesh

All India Institute of Medical Sciences, Raipur, Chhattisgarh

All India Institute of Medical Sciences, New Delhi, Delhi

Sir Ganga Ram Hospital, New Delhi, Delhi

SDS Tuberculosis Research Center & Rajiv Gandhi Institute of Chest Diseases, Bengaluru, Karnataka

St. Johns Medical College Hospital, Bengaluru, Karnataka

Sleep & Snoring Clinic & Research Centre, Nagpur, Maharashtra

Villoo Poonawalla Memorial Hospital, Pune, Maharashtra

Bhakti Vedanta Hospital and Research Institute, Thane, Maharashtra

All India Institute of Medical Sciences - Rishikesh, Rishikesh, Uttarakhand

Kirigaokatsuda Hospital, Kitakyushu, Fukuoka

RESM Respiratory and Sleep Medical Care Clinic, Yokohama, Kanagawa

Nakamura Clinic, Urasoe, Okinawa

Sakai City Medical Center, Sakai, Osaka

Osaka Kaisei Hospital, Osaka, Not set

Centro de Investigacion en Artritis y Osteoporosis SC, Mexicali, Baja California

RM Pharma Specialists - Unidad Especializada en Datos, Mexico City, Distrito Federal

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares, Mexico City, Distrito Federal

Diseno y Planeacion en Investigacion Medica, Guadalajara, Jalisco

Private Practice - Dr. Arechavaleta Granell Maria del Rosario, Guadalajara, Jalisco

CEINV Salud, Monterrey, Nuevo León

Centro de investigación y control metabólico, Monterrey, Nuevo León

Enclifar Ensayos Clínicos Farmacológicos Sc, Chihuahua, Not set

Chiayi Christian Hospital, Chiayi City, Chiayi

China Medical University Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Not set

Conditions: OSA, Overweight or Obesity

Learn More ›

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775

Recruiting

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona +16 locations

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

Learn More ›

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06722157

Recruiting

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longe... Read More

Gender:

ALL

Ages:

50 years and above

Trial Updated:

04/17/2025

Locations: Associated Retina Consultants, Gilbert, Arizona +47 locations

Associated Retina Consultants, Gilbert, Arizona

Associated Retina Consultants, Ltd., Phoenix, Arizona

Phoenix Retina Associates, Phoenix, Arizona

Retina Macula Institute of Arizona, Scottsdale, Arizona

Global Research Management, Glendale, California

Retina Associates of Southern California, Huntington Beach, California

Retinal Consultants Medical Group, Inc, Modesto, California

Eye Research Foundation, Newport Beach, California

Retina Consultants of San Diego, Poway, California

Retinal Consultants Medical Group, Sacramento, California

Orange County Retina, Santa Ana, California

Bay Area Retina Associates - Walnut Creek, Walnut Creek, California

Colorado Retina Associates, Lakewood, Colorado

Connecticut Eye Consultants, PC, Danbury, Connecticut

Retina Group of Florida, Fort Lauderdale, Florida

Eye Associates of Pinellas, Pinellas Park, Florida

Rand Eye Institute, Pompano Beach, Florida

Retina Vitreous Associates of Florida, Saint Petersburg, Florida

Southeast Retina Center, PC, Augusta, Georgia

University Retina and Macula Associates, Lemont, Illinois

Illinois Retina Associates - Oak Park, Oak Park, Illinois

Butchertown Clinical Trials, Louisville, Kentucky

Mid Atlantic Retina Specialists, Hagerstown, Maryland

Ophthalmic Consultants of Boston, Boston, Massachusetts

Retina Consultants of Minnesota, Edina, Minnesota

Mississippi Retina Associates, Madison, Mississippi

University of Missouri Health System, Columbia, Missouri

Envision Ocular, LLC, Bloomfield, New Jersey

Eye Associates of New Mexico, Albuquerque, New Mexico

Long Island Vitreoretinal Consultants - Westbury, Westbury, New York

Verum Research, LLC, Eugene, Oregon

Mid Atlantic Retina - Bethlehem, Bethlehem, Pennsylvania

Charleston Neuroscience Institute - Charleston, Charleston, South Carolina

Charles Retina Institute, Germantown, Tennessee

Tennessee Retina, Nashville, Tennessee

Austin Clinical Research, LLC, Austin, Texas

Retina Consultants of Texas-Beaumont-70319, Beaumont, Texas

Retina Consultants of Texas-Bellaire-67493, Bellaire, Texas

Retina Foundation of the Southwest, Dallas, Texas

Retina Consultants of Texas - Katy, Katy, Texas

Red River Research Partners, LLC, Plano, Texas

Retinal Consultants of San Antonio, San Antonio, Texas

Retina Consultants of Texas - Schertz, Schertz, Texas

Retina Consultants of Texas-The Woodlands-67575, The Woodlands, Texas

Retina Associates of Utah, Salt Lake City, Utah

Piedmont Eye Center, Lynchburg, Virginia

Spokane Eye Clinic, Spokane, Washington

Emanuelli Research & Development Center, Arecibo, Not set

Conditions: Macular Degeneration, Age-related, Geographic Atrophy

Learn More ›

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT06789913

Recruiting

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

Gender:

ALL

Ages:

2 years and above

Trial Updated:

04/17/2025

Locations: Arkansas Children's Hospital, Little Rock, Arkansas

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

Learn More ›